

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 7, 2002

Date of Report (Date of earliest event reported)

AMGEN INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction
of Incorporation)

000-12477

(Commission File Number)

95-3540776

(IRS Employer
Identification Number)

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA
(Address of principal
executive offices)

91320-1799

(Zip Code)

805-447-1000

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On May 7, 2002, Amgen Inc. purchased from F. Hoffman-La Roche Ltd. ("Roche") Roche's rights, assets and business related to Filgrastim and pegfilgrastim in the European Union, Switzerland and Norway. With regard to the EU, the effective date of the purchase is January 1, 2002. Under the terms of the agreement between the parties, Amgen will pay Roche \$137.5 million for this acquisition. Roche will continue as the licensee for Filgrastim and pegfilgrastim in certain countries in Eastern Europe, the Middle East, Africa, Asia and Latin America.

The press release announcing the transaction is attached to this Current Report as Exhibit 99.1.

Item 7(c). Exhibits.

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: May 10, 2002

By: /s/ Richard D. Nanula

Name: Richard D. Nanula
Title: Executive Vice President,
Finance, Strategy and
Communications, and Chief
Financial Officer

EXHIBIT INDEX

Exhibit Number -----	Document Description -----
99.1	Press Release dated May 7, 2002.

Amgen to Acquire Filgrastim and Pegfilgrastim in Europe From Roche

THOUSAND OAKS, Calif. and BASEL, Switzerland, May 7 /PRNewswire-FirstCall/ --
Roche and Amgen (Nasdaq: AMGN - news) announced today that Amgen has purchased

from Roche the assets and business related to filgrastim and pegfilgrastim in
the European Union, Switzerland and Norway.

Filgrastim and pegfilgrastim are white-cell boosting therapeutics that are used
to decrease the incidence of neutropenia, which can lead to patients contracting
potentially life threatening infections following chemotherapy. Filgrastim has
been commercialized by Amgen and Roche under the Neupogen(R) and Granulokine(R)
trade names. Amgen also currently markets in the U.S. pegfilgrastim, as
Neulasta(TM), a long-acting version of filgrastim.

In December 2001 Roche announced the planned merger of its Japanese subsidiary
with the Japanese company Chugai. As a result of this merger, Roche is selling
part of its European filgrastim and pegfilgrastim business to Amgen, as Chugai
commercializes a competitive drug.

Amgen will pay Roche \$137.5 million for this acquisition. Roche will continue as
the licensee for filgrastim and pegfilgrastim in certain countries in Eastern
Europe, the Middle East, Africa, Asia and Latin America.

About Filgrastim and Pegfilgrastim

Filgrastim and pegfilgrastim are a supportive part of treatment for many
patients receiving cancer chemotherapy. Some cancer drugs, in addition to
attacking the cancer, destroy the patient's white blood cells, which are
extremely important in fighting infection. Consequently, these patients are
prone to developing severe, and even life-threatening, infections. Filgrastim
and pegfilgrastim restore the number of white blood cells and thus improve their
ability to kill infecting micro-organisms.

About Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures
and markets important human therapeutics based on advances in cellular and
molecular biology. Amgen is headquartered in Thousand Oaks, CA, USA, with
European headquarters in Lucerne, Switzerland.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-oriented healthcare groups in the fields of pharmaceuticals,
diagnostics and vitamins. Roche's innovative products and services address
prevention, diagnosis and treatment of diseases, thus enhancing people's
well-being and quality of life.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.

Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of our products.

In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.

Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of May 7, 2002 and expressly disclaims any duty to update information contained in this press release.

CONTACT: Amgen

Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)

Roche:

Jacqueline Wallach, 41-61-688-8888

All trademarks used or mentioned in this release are legally protected.